BMO Capital Markets restated their positive rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report sent to investors on Wednesday, October 18th. BMO Capital Markets currently has a $152.00 price objective on the stock, up from their prior price objective of $145.00.
Other equities analysts have also issued reports about the company. J P Morgan Chase & Co increased their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an overweight rating in a research note on Wednesday, August 16th. BTIG Research lowered Johnson & Johnson from a neutral rating to a sell rating and set a $110.00 price objective for the company. in a research note on Friday, July 21st. UBS AG reissued a buy rating and set a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Wells Fargo & Company reissued a market perform rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, Jefferies Group LLC set a $145.00 price objective on Johnson & Johnson and gave the stock a hold rating in a research note on Tuesday, August 15th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $143.70.
Shares of Johnson & Johnson (NYSE JNJ) traded down 0.02% during mid-day trading on Wednesday, hitting $141.78. The company’s stock had a trading volume of 5,140,654 shares. The company has a market cap of $380.54 billion, a PE ratio of 24.66 and a beta of 0.78. The stock has a 50-day moving average of $135.26 and a 200-day moving average of $131.38. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $1.68 EPS. On average, equities research analysts forecast that Johnson & Johnson will post $7.28 EPS for the current year.
WARNING: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnson-jnj-receives-positive-rating-from-bmo-capital-markets.html.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.37%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Several large investors have recently modified their holdings of JNJ. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. IHT Wealth Management LLC grew its position in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson during the second quarter worth about $124,000. 65.89% of the stock is currently owned by institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.